Use of polymeric nanoparticles to guide and concentrate drugs against Parkinson's disease
Keywords:
Action research, reading and writing, biography genre, in-service training, critical writing, didactic proposal.Abstract
Parkinson's disease is considered worldwide to be the most devastating disease after Alzheimer's. It is characterized by the progressive destruction of dopaminergic neurons in the central nervous system. It affects approximately 2% of the general population. Motor and non-motor symptoms can be distinguished according to the degree of neuronal degeneration. The main function of the blood-brain barrier is the selective transport of substances into the brain. It is also distinguished by the abnormal accumulation of α-synuclein, which causes neuronal death. This compilation of information has been based on updated bibliography and scientific articles published in medical journals in order to report on updates in innovative treatments for this disease, since existing treatments are purely palliative. It is concluded that the use of polymeric nanoparticles is a system that is currently in clinical trials, but the results are satisfactory, promising, and greatly reduce adverse effects; Polylactic-co-glycolic acid is recommended for manufacturing nanocapsules incorporating chitosan and creating nanospheres that offer sustained drug release and facilitate crossing the BBB.
Downloads
References
Alabrahim, O. A. A. & Azzazy, H. M. E. S. (2022). Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson’s disease. Nanoscale Advances, 4(24), 5233–5244. Royal Society of Chemistry. https://doi.org/10.1039/d2na00524g
Alimohammadi, E., Khedri, M., Jahromi, A. M., Maleki, R., & Rezaian, M. (2020). Graphene-based nanoparticles as potential treatment options for parkinson’s disease: A molecular dynamics study. International Journal of Nanomedicine, 15, 6887–6903. https://doi.org/10.2147/IJN.S265140
Annu, A., Qamar, Z., Md, S., Alhakamy, N. A., Baboota, S., & Ali, J. (2022). An Insight to Brain Targeting Utilizing Polymeric Nanoparticles: Effective Treatment Modalities for Neurological Disorders and Brain Tumor. Frontiers in Bioengineering and Biotechnology, 10. Frontiers Media S.A. https://doi.org/10.3389/fbioe.2022.788128
Baskin, J., Jeon, J. E., & Lewis, S. J. G. (2021). Nanoparticles for drug delivery in Parkinson’s disease. Journal of Neurology, 268(5), 1981–1994. https://doi.org/10.1007/s00415-020-10291-x
Cai, H., Liu, D., Xue, W. W., Ma, L., Xie, H. T., & Ning, K. (2024). Lipid-based nanoparticles for drug delivery in Parkinson’s disease. In Translational Neuroscience, 15(1). Walter de Gruyter GmbH. https://doi.org/10.1515/tnsci-2022-0359
Castellani, S., Iaconisi, G. N., Tripaldi, F., Porcelli, V., Trapani, A., Messina, E., Guerra, L., Di Franco, C., Maruccio, G., Monteduro, A. G.,
Corbo, F., Di Gioia, S., Trapani, G., & Conese, M. (2024). Dopamine and Citicoline-Co-Loaded Solid Lipid Nanoparticles as Multifunctional Nanomedicines for Parkinson’s Disease Treatment by Intranasal Administration. Pharmaceutics, 16(8). https://doi.org/10.3390/pharmaceutics16081048
Cometa, S., Bonifacio, M. A., Trapani, G., Di Gioia, S., Dazzi, L., De Giglio, E., & Trapani, A. (2020). In vitro investigations on dopamine loaded Solid Lipid Nanoparticles. Journal of Pharmaceutical and Biomedical Analysis, 185. https://doi.org/10.1016/j.jpba.2020.113257
Fracp, V., Morris, H. R., Foltynie, T., Foltynie, T., Vijiaratnam, N., Simuni, T., Bandmann, O., & Morris, H. R. (2021). Progress towards therapies for disease modification in Parkinson’s disease. Review Lancet Neurol, 20. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00061-2/abstract
Gao, C., Liu, J., Tan, Y., & Chen, S. (2020). Freezing of gait in Parkinson’s disease: Pathophysiology, risk factors and treatments. Translational Neurodegeneration, 9 (1). BioMed Central Ltd. https://doi.org/10.1186/s40035-020-00191-5
García-Pardo, J., Novio, F., Nador, F., Cavaliere, I., Suárez-García, S., Lope-Piedrafita, S., Candiota, A. P., Romero-Gimenez, J., Rodríguez-
Galván, B., Bové, J., Vila, M., Lorenzo, J., & Ruiz-Molina, D. (2021). Bioinspired theranostic coordination polymer nanoparticles for intranasal dopamine replacement in parkinson’s disease. ACS Nano, 15(5), 8592–8609. https://doi.org/10.1021/acsnano.1c00453
Han, L. & Jiang, C. (2021). Evolution of blood–brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies. In Acta Pharmaceutica Sinica B, 11(8), 2306–2325. Chinese Academy of Medical Sciences. https://doi.org/10.1016/j.apsb.2020.11.023
Hernández-Parra, H., Cortés, H., Avalos-Fuentes, J. A., Del Prado-Audelo, M., Florán, B., Leyva-Gómez, G., Sharifi-Rad, J., & Cho, W. C. (2022). Repositioning of drugs for Parkinson’s disease and pharmaceutical nanotechnology tools for their optimization. Journal of Nanobiotechnology, 20(1). BioMed Central Ltd. https://doi.org/10.1186/s12951-022-01612-5
Jagaran, K., & Singh, M. (2022). Lipid Nanoparticles: Promising Treatment Approach for Parkinson’s Disease. In International Journal of Molecular Sciences, 23(16). MDPI. https://doi.org/10.3390/ijms23169361
Jankovic, J. & Tan, E. K. (2020). Parkinson’s disease: Etiopathogenesis and treatment. Journal of Neurology, Neurosurgery and Psychiatry, 91(8), 795–808. https://doi.org/10.1136/jnnp-2019-322338
Kim, M. & Bezprozvanny, I. (2023). Potential direct role of synuclein in dopamine transport and its implications for Parkinson’s disease pathogenesis. Biochemical and Biophysical Research Communications, 671, 18–25. https://doi.org/10.1016/j.bbrc.2023.05.110
Liu, H., Hua, M., Zheng, Q., Gao, Y., & Li, Z. (2023). Targeting the pathogenesis and boosting the therapeutic efficacy of Parkinson’s disease by advanced nanoparticles. MedComm - Biomaterials and Applications, 2(2). John Wiley and Sons Inc. https://doi.org/10.1002/mba2.47
Lombardo, S. M., Schneider, M., Türeli, A. E., & Türeli, N. G. (2020). Key for crossing the BBB with nanoparticles: The rational design. Beilstein Journal of Nanotechnology, 11, 866–883. Beilstein-Institut Zur Forderung der Chemischen Wissenschaften. https://doi.org/10.3762/BJNANO.11.72
Mogharbel, B. F., Cardoso, M. A., Irioda, A. C., Stricker, P. E. F., Slompo, R. C., Appel, J. M., de Oliveira, N. B., Perussolo, M. C., Saçaki, C. S., da Rosa, N. N., Dziedzic, D. S. M., Travelet, C., Halila, S., Borsali, R., & de Carvalho, K. A. T. (2022). Biodegradable Nanoparticles Loaded with Levodopa and Curcumin for Treatment of Parkinson’s Disease. Molecules, 27(9). https://doi.org/10.3390/molecules27092811
Nakmode, D. D., Day, C. M., Song, Y., & Garg, S. (2023). The Management of Parkinson’s Disease: An Overview of the Current Advancements in Drug Delivery Systems. Pharmaceutics, 15(5). MDPI. https://doi.org/10.3390/pharmaceutics15051503
Paccione, N., Rahmani, M., Barcia, E. & Negro, S. (2022). farmacia Agentes antiparkinsonianos en micro y nanosistemas poliméricos en investigación. https://doi.org/10.3390/farmaceutics15010013
Padilla-Godínez, F. J., Martínez-Becerril, H. A. & Guerra Crespo, M. (2023). ¿Qué hay de nuevo en la búsqueda para tratar la enfermedad de Parkinson? Revista Digital Universitaria, 24(4). https://doi.org/10.22201/cuaieed.16076079e.2023.24.4.12
Pardridge, W. M. (2023). Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport. Frontiers in Aging Neuroscience, 15. Frontiers Media SA. https://doi.org/10.3389/fnagi.2023.1276376
Satapathy, M. K., Yen, T. L., Jan, J. S., Tang, R. D., Wang, J. Y., Taliyan, R., & Yang, C. H. (2021). Solid lipid nanoparticles (Slns): An advanced drug delivery system targeting brain through bbb. Pharmaceutics, 13(8). MDPI AG. https://doi.org/10.3390/pharmaceutics13081183
Van Vliet, E. F., Knol, M. J., Schiffelers, R. M., Caiazzo, M. & Fens, M. H. A. M. (2023). Levodopa-loaded nanoparticles for the treatment of Parkinson’s disease. Journal of Controlled Release, 360, 212–224. https://doi.org/10.1016/j.jconrel.2023.06.026
Wu, X., Yuan, R., Xu, Y., Wang, K., Yuan, H., Meng, T., & Hu, F. (2024). Functionalized lipid nanoparticles modulate the blood-brain barrier and eliminate α-synuclein to repair dopamine neurons. Asian Journal of Pharmaceutical Sciences, 19(2). https://doi.org/10.1016/j.ajps.2024.100904
Yadav, V. K., Dhanasekaran, S., Choudhary, N., Nathiya, D., Thakur, V., Gupta, R., Pramanik, S., Kumar, P., Gupta, N., & Patel, A. (2025). Recent advances in nanotechnology for Parkinson’s disease: diagnosis, treatment, and future perspectives. Frontiers in Medicine, 12. Frontiers Media SA. https://doi.org/10.3389/fmed.2025.1535682
Zhao, N., Yang, Y., Zhang, L., Zhang, Q., Balbuena, L., Ungvari, G. S., Zang, Y. F., & Xiang, Y. T. (2021). Quality of life in Parkinson’s disease: A systematic review and meta-analysis of comparative studies. In CNS Neuroscience and Therapeutics, 27(3), 270–279. Blackwell Publishing Ltd. https://doi.org/10.1111/cns.13549
Zhao, Y., Xiong, S., Liu, P., Liu, W., Wang, Q., Liu, Y., Tan, H., Chen, X., Shi, X., Wang, Q., & Chen, T. (2020). Polymeric nanoparticles-based brain delivery with improved therapeutic efficacy of ginkgolide b in parkinson’s disease. International Journal of Nanomedicine, 15, 10453–10467. https://doi.org/10.2147/IJN.S272831
Zhu, F. D., Hu, Y. J., Yu, L., Zhou, X. G., Wu, J. M., Tang, Y., Qin, D. L., Fan, Q. Z., & Wu, A. G. (2021). Nanoparticles: A Hope for the Treatment of Inflammation in CNS. In Frontiers in Pharmacology, 12. Frontiers Media S.A. https://doi.org/10.3389/fphar.2021.683935
.png)
.png)
